Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry R Davis

Showing results (51-60 of 185) with videos related to

Pageof 19
Sort By:
Journal of the American College of Cardiology|November 21, 2009
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)L Julian Haywood, Charles E Ford, Richard S Crow, et al.
Journal of Hypertension|January 25, 2020
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialStephen P Juraschek, Lara M Simpson, Barry R Davis, et al.
Pharmacogenetics and Genomics|March 6, 2012
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT studyAmy I Lynch, John H Eckfeldt, Barry R Davis, et al.
Clinical Trials (London, England)|November 11, 2005
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paperKay Dickersin, Barry R Davis, Dennis O Dixon, et al.
Annals of Internal Medicine|June 9, 2016
Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial ExecutionBryan R Luce, Jason T Connor, Kristine R Broglio, et al.
JAMA|January 24, 2008
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertensionAmy I Lynch, Eric Boerwinkle, Barry R Davis, et al.
Pharmacogenetics and Genomics|April 9, 2009
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT studyAmy I Lynch, Eric Boerwinkle, Barry R Davis, et al.
BMJ Open|May 25, 2019
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)Kazem Rahimi, Dexter Canoy, Milad Nazarzadeh, et al.
Annals of Internal Medicine|September 3, 2002
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack TrialBarry R Davis, Jeffrey A Cutler, Curt D Furberg, et al.
Journal of the American Geriatrics Society|June 6, 2020
Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older AdultsC Barrett Bowling, Richard Sloane, Carl Pieper, et al.
Pageof 19

Showing results (51-60 of 185) with videos related to

Sort By:
Pageof 19
Journal of the American College of Cardiology|November 21, 2009
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)L Julian Haywood, Charles E Ford, Richard S Crow, et al.
Journal of Hypertension|January 25, 2020
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialStephen P Juraschek, Lara M Simpson, Barry R Davis, et al.
Pharmacogenetics and Genomics|March 6, 2012
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT studyAmy I Lynch, John H Eckfeldt, Barry R Davis, et al.
Clinical Trials (London, England)|November 11, 2005
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paperKay Dickersin, Barry R Davis, Dennis O Dixon, et al.
Annals of Internal Medicine|June 9, 2016
Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial ExecutionBryan R Luce, Jason T Connor, Kristine R Broglio, et al.
JAMA|January 24, 2008
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertensionAmy I Lynch, Eric Boerwinkle, Barry R Davis, et al.
Pharmacogenetics and Genomics|April 9, 2009
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT studyAmy I Lynch, Eric Boerwinkle, Barry R Davis, et al.
BMJ Open|May 25, 2019
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC)Kazem Rahimi, Dexter Canoy, Milad Nazarzadeh, et al.
Annals of Internal Medicine|September 3, 2002
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack TrialBarry R Davis, Jeffrey A Cutler, Curt D Furberg, et al.
Journal of the American Geriatrics Society|June 6, 2020
Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older AdultsC Barrett Bowling, Richard Sloane, Carl Pieper, et al.
Pageof 19